AU2010320823B2 - Pharmaceutical composition comprising propofol - Google Patents

Pharmaceutical composition comprising propofol Download PDF

Info

Publication number
AU2010320823B2
AU2010320823B2 AU2010320823A AU2010320823A AU2010320823B2 AU 2010320823 B2 AU2010320823 B2 AU 2010320823B2 AU 2010320823 A AU2010320823 A AU 2010320823A AU 2010320823 A AU2010320823 A AU 2010320823A AU 2010320823 B2 AU2010320823 B2 AU 2010320823B2
Authority
AU
Australia
Prior art keywords
composition
propofol
oral
carbon atoms
sfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010320823A
Other languages
English (en)
Other versions
AU2010320823A1 (en
Inventor
Bastian Theisinger
Sonja Theisinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaliq GmbH
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of AU2010320823A1 publication Critical patent/AU2010320823A1/en
Application granted granted Critical
Publication of AU2010320823B2 publication Critical patent/AU2010320823B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010320823A 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol Active AU2010320823B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09014548.3 2009-11-23
EP09014548A EP2332525A1 (en) 2009-11-23 2009-11-23 Pharmaceutical composition comprising propofol
PCT/EP2010/067938 WO2011061332A1 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Publications (2)

Publication Number Publication Date
AU2010320823A1 AU2010320823A1 (en) 2012-07-12
AU2010320823B2 true AU2010320823B2 (en) 2014-06-26

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010320823A Active AU2010320823B2 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Country Status (12)

Country Link
US (1) US8796340B2 (enExample)
EP (2) EP2332525A1 (enExample)
JP (1) JP5707009B2 (enExample)
KR (1) KR20120104262A (enExample)
CN (1) CN102753159B (enExample)
AU (1) AU2010320823B2 (enExample)
BR (1) BR112012012108A2 (enExample)
CA (1) CA2776855C (enExample)
ES (1) ES2450423T3 (enExample)
IN (1) IN2012DN03130A (enExample)
MX (1) MX2012005881A (enExample)
WO (1) WO2011061332A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
EP2708228B1 (en) * 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
WO2016061538A1 (en) 2014-10-16 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6262126B1 (en) * 1995-09-29 2001-07-17 Hasso Meinert Semi-fluorinated alkanes and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2110126B9 (de) * 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262126B1 (en) * 1995-09-29 2001-07-17 Hasso Meinert Semi-fluorinated alkanes and their use
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages

Also Published As

Publication number Publication date
EP2503999A1 (en) 2012-10-03
MX2012005881A (es) 2012-06-19
EP2503999B1 (en) 2013-12-25
CN102753159B (zh) 2014-03-12
KR20120104262A (ko) 2012-09-20
BR112012012108A2 (pt) 2016-04-05
AU2010320823A1 (en) 2012-07-12
CA2776855C (en) 2017-10-24
CA2776855A1 (en) 2011-05-26
US8796340B2 (en) 2014-08-05
JP5707009B2 (ja) 2015-04-22
WO2011061332A1 (en) 2011-05-26
US20120238639A1 (en) 2012-09-20
CN102753159A (zh) 2012-10-24
JP2013511496A (ja) 2013-04-04
EP2332525A1 (en) 2011-06-15
IN2012DN03130A (enExample) 2015-09-18
ES2450423T3 (es) 2014-03-24

Similar Documents

Publication Publication Date Title
CA2776855C (en) Pharmaceutical composition comprising propofol
KR101910213B1 (ko) 부분불소화된 알칸을 포함하는 수중유형 에멀젼
US5496537A (en) Propofol hydrofluorocarbon propellant formulations
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
JP2021508670A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CA3175130A1 (en) Treatment with powdered intranasal epinephrine
EP1515711A1 (en) Pharmaceutical composition
JP2023547040A (ja) ピロロピリジン－アニリン化合物による、認知機能不全の処置方法
JP2007515425A (ja) 医薬組成物
WO2022081297A1 (en) Compositions and methods for lowering intracranial pressure by intranasal agent administration
HK1172272A (en) Pharmaceutical composition comprising propofol
EP3407875A1 (en) Aqueous pharmaceutical formulation comprising propofol
EP4483870B1 (en) Aqueous retinol formulations
HK40054634B (en) Aqueous paediatric retinol formulations
WO2025205960A1 (ja) エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ
HK1235272A1 (en) O/w-emulsions comprising semifluorinated alkanes
HK1235272B (en) O/w-emulsions comprising semifluorinated alkanes
KR20010014366A (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)